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A B S T R A C T
The inositol pyrophosphate, diphosphoinositol pentakisphosphate (IP7), is thought to negatively regulate the
critical insulin signaling protein Akt/PKB. Knockdown of the IP7-generating inositol hexakisphosphate kinase 1
(IP6K1) results in a concomitant increase in signaling through Akt/PKB in most cell types so far examined. Total
in vivo knockout of IP6K1 is associated with a phenotype resistant to high-fat diet, due to enhanced Akt/PKB
signaling in classic insulin regulated tissues, counteracting insulin resistance. In contrast, we have shown an
important positive role for IP6K1 in insulin exocytosis in the pancreatic β-cell. These cells also possess functional
insulin receptors and the feedback loop following insulin secretion is a key aspect of their normal function. Thus
we examined the effect of silencing IP6K1 on the activation of Akt/PKB in β-cells. Silencing reduced the glucose-
stimulated increase in Akt/PKB phosphorylation on T308 and S473. These effects were reproduced with the
selective pan-IP6K inhibitor TNP. The likely explanation for IP7 reduction decreasing rather than increasing Akt/
PKB phosphorylation is that IP7 is responsible for generating the insulin signal, which is the main source of Akt/
PKB activation. In agreement, insulin receptor activation was compromised in TNP treated cells. To test whether
the mechanism of IP7 inhibition of Akt/PKB still exists in β-cells, we treated them at basal glucose with an insulin
concentration equivalent to that reached during glucose stimulation. TNP potentiated the Akt/PKB phosphor-
ylation of T308 induced by exogenous insulin. Thus, the IP7 regulation of β-cell Akt/PKB is determined by two
opposing forces, direct inhibition of Akt/PKB versus indirect stimulation via secreted insulin. The latter me-
chanism is dominant, masking the inhibitory effect. Consequently, pharmacological strategies to knock down
IP6K activity might not have the same positive output in the β-cell as in other insulin regulated tissues.
1. Introduction
Inositol pyrophosphates are now considered to be key cellular reg-
ulators with roles in signal transduction and in a broad spectrum of
critical cellular processes, including vesicle trafficking and exocytosis,
apoptosis and cell proliferation, telomere length and cytoskeletal reg-
ulation as well as polyphosphate homeostasis [1–8]. Some of these
processes may be driven by action of the inositol pyrophosphate, 5-
diphosphoinositol pentakisphosphate (5-PPIP5 or IP7) on the key sig-
naling protein Akt/PKB [9–14]. Global IP6K1 gene deletion in mice has
revealed that IP7 serves as a potent Akt/PKB inhibitor [9]. This has
important consequences for insulin signaling in general and in parti-
cular the in vivo knockout of IP6K1 leads to enhanced Akt/PKB
signaling in classic insulin-responsive tissues, including liver, skeletal
muscle and white fat [8,9]. The resulting increased insulin sensitivity in
these tissues creates an animal that overcomes high fat diet-induced
insulin resistance [9].
We have previously studied IP7 in the pancreatic β-cell where it acts
both to prepare the β-cell for exocytosis [3,15], and to regulate initial
insulin secretion [16]. In these cells glucose-stimulated IP7 generation
is largely mediated by IP6K1 that acts as a metabolic sensor transducing
the glucose-mediated increase in the ATP/ADP ratio into first phase
insulin secretion [16]. This is an important observation as it is the loss
of first phase secretion that is characteristic of early diabetes and even
pre-diabetes [17,18]. The importance of IP6K1 for β-cell exocytosis is in
contrast to its negative impact on other insulin-sensitive tissues in
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which knockdown of IP6K1 leads to protection against insulin re-
sistance due to enhanced Akt/PKB signaling.
The target(s) for IP7 in β-cells are unknown, but based on the lit-
erature, Akt/PKB is a possible candidate. However, it is unlikely that
inhibition of Akt/PKB by IP7 can explain this inositol pyrophosphate's
action in promoting insulin secretion as most reports suggest that in-
hibition of Akt/PKB has a negative effect on exocytosis [19–21], with
one exception [22]. An important aspect of β-cell regulation and signal
transduction is the fact that the secreted insulin feeds back on its own
receptors thus re-initializing a second wave of signaling, including the
activation of Akt/PKB [3,19,23]. This secondary signaling has been
shown to be important for many aspects of β-cell function, including the
biosynthesis and secretion of insulin itself [19,23]. Clearly, this unique
feedback loop suggests that insulin resistance in the β-cell may also be a
factor in the development of the diabetic phenotype.
We have now investigated the consequence of IP6K1 knockdown in
pancreatic β-cells with respect to Akt/PKB signaling. The prediction,
based on the results of IP6K1 knockdown in other insulin-sensitive cells
[8,9], was that IP6K1 reduction and subsequent lowering of IP7 would
lead to enhanced Akt/PKB signaling. However, our experiments using
glucose, the physiological stimulus of β-cells, revealed the complete
opposite. IP7 reduction via either RNAi mediated IP6K1 knockdown or
the use of a specific pan-IP6K inhibitor, resulted in decreased rather than
increased activation of Akt/PKB. The reason for this different outcome is
the dominant positive action of IP7 on Akt/PKB via the unique auto-
crine insulin feedback loop present in β-cells. This effect overcomes the
direct inhibition of Akt/PKB by IP7.
2. Experimental procedures
2.1. Chemicals
All cell culture reagents were obtained from Life Technologies
(Stockholm, Sweden). Common chemicals and N2-(m-Trifluorobenzyl),
N6-(p-nitrobenzyl) purine (TNP) were purchased either from Sigma
(Stockholm, Sweden) or Merck KGaA (Darmstad, Germany), and insulin
was obtained from Novo Nordisk (Denmark). Antibodies against
phospho-Akt at T308 (#9275, #4056, #13038) and S473 (#9271), Akt
(#9272) and β-actin (#8H10D10), were purchased from Cell Signaling
Technology Inc. (Danvers, MA, USA). Antibodies against β-actin were
from Thermofisher Scientific (MA5-15739) and Cell Signaling
Technology (#8H10D10). The antibodies anti-phospho-IRS1 Y608
(#09-432) and anti-IRS1 (#06-248) were purchased from Millipore
(Darmstadt, Germany) and the antibody anti-IP6K1 (#HPA040825)
was from Sigma. Secondary antibodies were purchased from either Cell
Signaling Technology, Thermofisher Scientific (MA, USA) or Sera care
Life Sciences (Milford, MA, USA).
2.2. Cell culture
MIN6m9 cells, a generous gift from Dr. Seino [24], were cultured in
complete DMEM containing 11mM glucose, 10% FBS, 100 units/ml
penicillin G, 100 μg/ml streptomycin-sulphate and 5 nl/ml β-mercap-
toethanol in 5% CO2 incubator at 37 °C.
2.3. RNA silencing
MIN6m9 cells were silenced as described previously [15]. siRNAs
specific for IP6K1 (ID= 188560 and 71758) or non-targeting control
(ID= 4611 and 4613) were purchased from Ambion Inc./ Thermo-
fisher Scientific (Austin, TX).
2.4. Static incubation assays
MIN6m9 cells were seeded in complete DMEM. On the day of the
experiment, the cells were preincubated for 1 h in modified KREBS
buffer (119mM NaCl, 4.6mM KCl, 2mM CaCl2, 1 mM MgSO4, 0.15mM
Na2HPO4, 0.4mM KH2PO4, 5mM NaHCO3, 0.5mg/ml BSA, 20mM
HEPES pH 7.4) containing 0.5 mM glucose. For experiments involving
TNP-treatment, 10 μM TNP or vehicle (DMSO) were added during the
last 30min of preincubation. After preincubation, the cells were sti-
mulated with KREBS buffer containing either 0.5mM glucose or 10mM
glucose for 3min in the presence of vehicle (DMSO) or 10 μM TNP and
in some cases exogenous insulin (58 ng/ml). The cells were then lysed
for protein extraction followed by western blotting as described in the
following section. In experiments where we investigated the effect of
TNP on insulin secretion, the stimulation buffer was collected for in-
sulin measurement and the cells were lysed with M-PER (Thermofisher
Scientific) for protein normalization using a Pierce™ BCA protein assay
kit (Thermofisher Scientific). Insulin was quantified using an AlphaLISA
immunoassay kit (Perkin Elmer, Waltham, MA), according to the
manufacturer's instructions [16].
2.5. Western blotting
Cells were lysed with RIPA buffer containing protease and phos-
phatase inhibitors (Roche Diagnostics, Stockholm, Sweden). The cell
lysate was sonicated and centrifuged at 16,000g for 15min. Protein
content in the supernatant was measured by the BCA assay (Pierce™
BCA Protein Assay Kit). The same amount of proteins from each sample
were denatured by heating in Laemmli sample buffer, separated by
SDS–PAGE and transferred to nitrocellulose membranes [25]. Mem-
branes were blocked with either 5% BSA or 5% skim milk in Tris-buf-
fered saline containing 0.05% Tween 20 (TBST, pH 7.6) and then in-
cubated with primary antibodies diluted in the same buffer at 4 °C
overnight. The membranes were then washed with TBST for 1 h, in-
cubated with HRP-conjugated secondary antibody [25], washed again
with TBST and developed with SuperSignal West Femto Chemilumi-
nescent Substrate (Thermofisher scientific). The chemiluminescence
signal was detected by either a CCD camera or X-ray film exposure. The
images were quantified by either ImageJ 1.48v or Image LabTM,
BioRad. For quantifying different proteins from the same blot, the
membrane was stripped and re-probed with respective antibodies.
Western blotting results were normalized by sum of the replicates [26]
for quantitative comparison and statistical analysis.
2.6. Statistical analysis
The data, expressed as means± SEM, were statistically analyzed
with GraphPad Prism software version 5.0. Detailed information on the
statistical analysis of specific data sets is described in the respective
figure legends and Supplemental Tables S1 and S2.
3. Results and discussion
3.1. IP6K1 serves to activate, not inhibit, Akt/PKB in insulin secreting cells
In β-cells the secretion of endogenous insulin is the physiologically
relevant manner in which insulin stimulates insulin receptors and thus
activates Akt/PKB. This is in contrast to how insulin is introduced in
other cells. Insulin secretion in mouse β-cells including cell lines con-
sists of two phases, with the early first phase dominating over the later
second phase. Using insulin secreting MIN6m9 cells, we have pre-
viously established that glucose stimulation induces a peak in IP7 pro-
duction and insulin exocytosis after 3min [16]. This increase in IP7
levels and its subsequent stimulation of first phase insulin secretion are
driven mainly by IP6K1 [16]. Existing studies, including those carried
out with the IP6K1 knockout mice [8,9], have clearly shown an in-
creased Akt/PKB activity when IP6K1 is knocked down in the classic
insulin sensitive tissues including liver, skeletal muscle and white fat, as
well as in a number of other cell types [8,9, 14, 27–33]. The effect of
IP6K1/IP7 knockdown on Akt/PKB activity is most marked in mice
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under pathological conditions such as high-fat diet feeding [9,10],
aging [14] or following various cardiac pathologies [30,31]. In some
cell systems, IP6K1/IP7 knockdown does not seem to impact Akt/PKB
activity [34]. However, in this context insulin-sensitive β-cells were not
investigated. Based on the above dynamics of glucose-induced IP7
production we would anticipate a maximal impact of IP7 on Akt/PKB at
3min in MIN6m9 cells.
In order to examine the effect of IP6K1 knockdown on Akt/PKB we
interrogated the two phosphorylation sites T308 and S473 using wes-
tern blotting. These sites are established surrogates for the activation of
Akt/PKB [35]. Glucose stimulation for 3min caused a 2.5-fold increase
in phosphorylation of T308 in MIN6m9 cells, indicating an increased
Akt/PKB activity (Fig. 1A and B). There was also increased phosphor-
ylation of the S473 site (Fig. 1A and C). Both Akt/PKB phosphorylation
sites are activated by IP6K1 silencing in other insulin responsive cells
(e.g. muscle) [8,9]. We discovered that silencing IP6K1 leads to a re-
duction, not activation, in Akt/PKB activity in β-cells (Fig. 1A–C), in
contrast to other cell models. The magnitude of the inhibitory effect and
the interplay with glucose stimulation was slightly different between
the two phosphorylation sites. In the case of the T308 site (Fig. 1A and
B), silencing IP6K1 prevented the increase in T308 phosphorylation
after 3min glucose stimulation. There was no effect on basal phos-
phorylation. In the case of the S473 site (Fig. 1A and C) glucose-sti-
mulation also increased phosphorylation at this position, but to a lesser
extent than at T308. It was also possible to observe a significant
reduction in phosphorylation of this site upon silencing of IP6K1. IP6K1
silencing showed a similar tendency in Akt/PKB phosphorylation
during a longer time of glucose stimulation (10min), although Akt/PKB
phosphorylation was less pronounced (Fig. S1). Overall, these data
suggest that IP7 may act by positively, rather than negatively, reg-
ulating Akt/PKB activity in β-cells.
3.2. Pharmacological IP6K inhibition by TNP also decreases Akt/PKB
activation
RNAi mediated knockdown is a long-term approach to assess pro-
tein function and clearly the cell may adapt to this intervention.
Therefore the disparity between our results and data from other insulin-
responsive cells could be the result of specific longer-term and thus
more indirect changes in β-cell physiology. To address this we used an
alternative pharmacological approach. We subjected the cells to 3min
glucose stimulation in the presence or absence of the pan-IP6K inhibitor
TNP. Fig. 1(D–F) illustrates that essentially the same pattern of reduced
phosphorylation of T308 and S473 in Akt/PKB occurred in TNP treated
MIN6m9 cells as in IP6K1 knockdown. Together these data substantiate
the idea that the relationship between IP7/IP6K1 and Akt/PKB phos-
phorylation is rather different in the pancreatic β-cell compared to
several other cell types studied.
Fig. 1. Silencing of IP6K1 or treatment with TNP inhibits glucose-stimulated Akt/PKB phosphorylation in insulin secreting MIN6m9 cells. The involvement of IP7 in
Akt/PKB phosphorylation was studied in MIN6m9 cells using western blotting. Cells that were preincubated for 1 h at basal glucose condition (0.5mM) were
stimulated with 10mM glucose for 3 min. For experiments involving TNP-treatment, 10 μM TNP or vehicle (DMSO) were also added during the last 30min of
preincubation. (A) Representative immunoblot out of six showing Akt phosphorylation obtained upon 0.5mM glucose or 10mM glucose treatment in control siRNA
or IP6K1 siRNA treated cells. (B) Glucose mediated increase in Akt-T308 phosphorylation was abolished upon silencing IP6K1. (C) Silencing IP6K1 also decreased
Akt-S473 phosphorylation under high glucose condition. (D) Representative immunoblot out of four showing Akt phosphorylation obtained upon 0.5mM glucose or
10mM glucose stimulation in DMSO or TNP treated cells. (E) TNP treatment decreased glucose mediated increase in Akt-T308 phosphorylation. (F) TNP treatment
decreased Akt-S473 phosphorylation under high glucose condition. Data are presented as means± SEM, n=6 experiments (silencing) or n=4 (TNP), *p < .05,
**p < .01, ***p < .001 using Two-way ANOVA (Supplemental Table S1). siCON, control siRNA; siIP6K1, IP6K1 siRNA; 0.5G, 0.5mM glucose; 10G, 10mM glucose.
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3.3. Is the impact of IP6K knockdown on Akt/PKB mediated via the insulin
feedback loop?
At first sight our data suggest that IP7 stimulates rather than inhibits
Akt/PKB, diametrically opposing previous results in some other cells
(e.g. white fat, skeletal muscle and liver). [8,9]. We decided to in-
vestigate this paradox further, focusing on one of the distinctive prop-
erties of the pancreatic β-cell, namely the insulin feedback loop. Our
earlier work established that secreted insulin feeds back on its own
receptor, thus re-initializing signaling events, particularly those in-
stigated through PI3K and Akt/PKB [3,19,23,36]. Thus in the β-cell the
compromised insulin secretion caused by silencing IP6K1 [16] should
reduce the insulin signaling pathway that stimulates Akt/PKB (Model in
Fig. 2). To clarify this we examined the phosphorylation of the insulin
receptor substrate (IRS1) at the Y608 site, which is an initial activation
step following the engagement of the insulin receptor by insulin.
MIN6m9 cells exhibited a glucose-stimulated increase in insulin secre-
tion (Fig. 3A) and IRS1 phosphorylation (Fig. 3B and C). Both these
were reduced upon TNP treatment (Fig. 3), when production of IP7 is
curtailed [37]. This is unlikely to be due to interfering with a possible
interaction of IP7 with IRS1 phosphorylation because in the previous
studies on muscle cells [9] reduction of IP7 did not affect insulin-
stimulated IRS1 phosphorylation. That is, there was no indication of a
direct effect of IP7 on IRS1. We propose that the dominant effect of IP7
on the pancreatic β-cell Akt/PKB is to indirectly increase its kinase
activity via increased exocytosis and insulin feedback loop (Fig. 2). Of
course, this does not exclude the possibility that IP7 may also directly
inhibit Akt/PKB in these cells. In order to address this issue we needed
to by-pass the impact of IP7 on insulin secretion.
3.4. Direct effects of IP7 on Akt-T308 phosphorylation
We examined independently whether in β-cells the mechanism of
direct IP7 action found in other insulin-sensitive cells is masked by the
autocrine insulin feedback. We studied the effects of the TNP treatment
in cells exposed to exogenous insulin (58 ng/ml) under basal conditions
(0.5mM glucose) in order to mimic the extracellular insulin levels
reached during glucose stimulation. Fig. 4A shows that exogenous in-
sulin caused a significant elevation in T308 phosphorylation in control
cells. This increase in phosphorylation was similar to that elicited by
glucose in the same experiment. However, when cells were stimulated
with insulin in the presence of TNP this elevation in T308 phosphor-
ylation was significantly enhanced, whereas there was no difference in
S473 phosphorylation (Fig. 4B). These findings are consistent with the
observations performed in other cell systems, e.g. Fig. S2A in [9]. Our
data thus indicate that IP7 inhibits T308 phosphorylation also in β-cells.
They confirm the idea that the relationship between IP6K1 and Akt/
PKB is not fundamentally different from cells examined in other studies,
but that the autocrine insulin feedback loop driven by IP7-mediated
exocytosis is the dominant factor in determining the overall impact of
IP7 on Akt/PKB activity in β-cells.
4. Conclusions
Our findings expose a unique interplay between IP7 and Akt/PKB in
pancreatic β-cells. Two elements create this distinctive situation. The
first is the importance of IP7 in insulin secretion [3,16]. The second is
the autocrine feedback of the secreted insulin on β-cell insulin re-
ceptors, which activates Akt/PKB [23]. When you combine these two
elements, reducing IP7 concentrations also reduces, indirectly, Akt/PKB
signaling. This feedback effect dominates over the inhibitory action the
pyrophosphate has on Akt/PKB (see model in Fig. 2). Therefore, our
data are not contradictory to the established thinking regarding IP7
action on Akt/PKB, but reflect inositol pyrophosphate metabolism in a
more complex biological setting. These results also imply that
Fig. 2. Model of possible regulation of Akt/PKB by inositol pyrophosphates in
β-cells. Proposed model illustrates that although IP7 may inhibit Akt/PKB in
pancreatic β-cells, its dominant effect could be to activate Akt/PKB, through the
insulin feedback loop.
Fig. 3. The pan-IP6K inhibitor TNP blocks glucose-stimulated insulin secretion and insulin-mediated activation of IRS1 in MIN6m9 cells. (A) Stimulation of MIN6m9
cells with 10mM glucose induced a significant increase in insulin secretion. In contrast, in the presence of 10 μM TNP, 10mM glucose did not induce any secretion.
Data are presented as means± SEM, n= 4 experiments, ***p < .001 using Two-way ANOVA (Supplemental Table S1). The TNP effect on insulin-mediated IRS1
phosphorylation was studied in MIN6m9 cells by immunoblotting. (B) Representative immunoblot out of four showing IRS1 phosphorylation obtained upon 0.5mM
glucose or 10mM glucose treatment in DMSO or TNP treated cells. (C) There was a significant increase in IRS1 phosphorylation upon 10mM glucose stimulation for
3 min in the samples treated with vehicle (DMSO). Inhibiting the glucose-mediated increase in insulin secretion by 10 μM TNP treatment (A), reduced IRS1 phos-
phorylation. Data are presented as means± SEM, n= 4 experiments, ***p < .001 using Two-way ANOVA (Supplemental Table S1). 0.5G, 0.5mM glucose; 10G,
10mM glucose.
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inhibiting the production of IP7 in pancreatic β-cells could lead to an
insulin resistance phenotype in these cells. However, one must be
careful to extrapolate these in vitro findings to the situation in vivo
which will be necessarily more intricate, both in terms of normal
physiology and metabolic diseases [8,11].
Considering treatment strategies for obesity and type 2 diabetes,
IP6K inhibition seems to be beneficial because it decreases insulin re-
sistance in peripheral tissues, as indicated by the ability of TNP to
ameliorate diet induced obesity in mice [10]. In terms of the β-cell, our
concern is that IP6K1 inhibition disrupts insulin secretion. This seems
to be compensated by increase of insulin sensitivity in peripheral tissues
[9]. It is theoretically possible that TNP treatment may also prevent
hypersecretion of insulin, a putative contributor to the insulin re-
sistance. However, in the later stages of the disease, when β-cell insulin
secretion is significantly decreased, further reduction of secretion
mediated by TNP, or future IP6K inhibiting drugs, would be undesir-
able. In conclusion, potential modulation of IP6K activity in diabetic
patients will have to be matched carefully with the stage of disease
development.
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